Cambridge, United States
PhaseV, founded in 2023 and headquartered in the United States, is making strides in transforming clinical development. This Boston-based technology company is known for its slogan: Adaptive. Causal. Intuitive. The firm offers an enterprise-ready AI/ML platform designed to expedite clinical decisions, minimize trial risks, and enhance portfolio efficiency.
Key innovations include the Trial Optimizer, which promises up to a 50% cost reduction, 40% fewer enrollment requirements, and a 30%+ increase in trial success probabilities. Their ClinOps Optimizer improves site selection by leveraging patient-level insights, while the Lifecycle Management module integrates causal evidence to guide portfolio decisions.
Recently securing a $50.00M Series A investment on 01 May 2025, with backing from prominent investors such as LionBird, Insight Partners, Viola Ventures, Accel, and Exor Ventures, PhaseV is well-positioned to optimize clinical development at every stage.
